Haemonetics (NYSE: HAE) reported Q3 EPS of $1.31, $0.06 better than the analyst estimate of $1.25. Revenue for the quarter came in at $338.97 million versus the consensus estimate of $331.91 million.

For earnings history and earnings-related data on Haemonetics (HAE) click here.